Cross-Tissue Transcriptomic Analysis of Human Secondary Lymphoid Organ-Residing ILC3s Reveals a Quiescent State in the Absence of Inflammation by Bar-Ephraim, Y.E. (Yotam E.) et al.
ResourceCross-Tissue Transcriptomic Analysis of Human
Secondary Lymphoid Organ-Residing ILC3s Reveals
a Quiescent State in the Absence of InflammationGraphical AbstractHighlightsd Human ILC3s in lymph nodes and spleen lack the
transcription of classical ILC3 cytokines
d Human ILC3s in lymph nodes and spleen can respond to
inflammatory cytokines
d NKp44 expression and cytokine production are separately
regulatedBar-Ephraim et al., 2017, Cell Reports 21, 823–833
October 17, 2017 ª 2017 The Author(s).
https://doi.org/10.1016/j.celrep.2017.09.070Authors
YotamE. Bar-Ephraim, Ferry Cornelissen,
Natalie Papazian, ..., Rogier M. Reijmers,
Reina E. Mebius, Tom Cupedo
Correspondence
r.mebius@vumc.nl (R.E.M.),
t.cupedo@erasmusmc.nl (T.C.)
In Brief
Bar-Ephraim et al. describe a cross-
tissue transcriptional comparison of
human ILC3s and show that ILC3s in
lymph nodes and spleen share a
transcriptional profile that is distinct from
that of tonsil ILC3s. Lymphoid organ
ILC3s are a substantial pool of resting
cells that can be recruited into immune
responses upon local activation.Data and Software AvailabilityE-MTAB-5909
Cell Reports
ResourceCross-Tissue Transcriptomic Analysis of Human
Secondary Lymphoid Organ-Residing ILC3s Reveals
a Quiescent State in the Absence of Inflammation
Yotam E. Bar-Ephraim,1,6 Ferry Cornelissen,2,6 Natalie Papazian,2 Tanja Konijn,1 Remco M. Hoogenboezem,2
Mathijs A. Sanders,2 Bart A. Westerman,3 Mehmet Go¨n€ultas,4 Jaap Kwekkeboom,5 Joke M.M. Den Haan,1
Rogier M. Reijmers,1 Reina E. Mebius,1,7,* and Tom Cupedo2,7,8,*
1Department of Molecular Cell Biology and Immunology, VU University Medical Center, 1081 HZ Amsterdam, the Netherlands
2Department of Hematology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands
3Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, 1081 HV Amsterdam, the Netherlands
4Department of Otolaryngology, Slotervaart Hospital, 1066 EC Amsterdam, the Netherlands
5Department of Gastroenterology and Hepatology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands
6These authors contributed equally
7Senior author
8Lead Contact
*Correspondence: r.mebius@vumc.nl (R.E.M.), t.cupedo@erasmusmc.nl (T.C.)
https://doi.org/10.1016/j.celrep.2017.09.070SUMMARY
A substantial number of human and mouse group 3
innate lymphoid cells (ILC3s) reside in secondary
lymphoid organs, yet the phenotype and function of
these ILC3s is incompletely understood. Here, we
employed an unbiased cross-tissue transcriptomic
approach to compare human ILC3s from non-in-
flamed lymph nodes and spleen to their phenotypic
counterparts in inflamed tonsils and from circulation.
These analyses revealed that, in the absence of
inflammation, lymphoid organ-residing ILC3s lack
transcription of cytokines associated with classical
ILC3 functions. This was independent of expression
of the natural cytotoxicity receptor NKp44. However,
and in contrast to ILC3s from peripheral blood,
lymphoid organ-residing ILC3s express activating
cytokine receptors and have acquired the ability to
be recruited into immune responses by inflammatory
cytokines. This comprehensive cross-tissue dataset
will allow for identification of functional changes in
human lymphoid organ ILC3s associatedwith human
disease.
INTRODUCTION
In recent years, group 3 innate lymphoid cells (ILC3s) emerged
as cytokine-secreting effector cells at mucosal barriers that are
involved in maintenance of barrier integrity and initiation of im-
mune responses upon infection (Artis and Spits, 2015). ILC3s
are cells of lymphoid origin (Montaldo et al., 2014; Scoville
et al., 2016) that are defined by lack of known lineage markers
but marked by expression of the alpha chain of the interleukin-7
(IL-7) receptor (IL-7Ra, CD127) and the nuclear hormone recep-
tor retinoic acid orphan receptor (ROR) gt (Artis and Spits,Cell
This is an open access article under the CC BY-N2015; Spits et al., 2013). ILC3s have been extensively described
as resident cells at epithelial and mucosal surfaces, where they
safeguard barrier integrity by secretion of IL-22 in both mice
and humans (Artis and Spits, 2015; Crellin et al., 2010a,
2010b; Hazenberg and Spits, 2014). In addition to mucosal tis-
sues, ILC3s are found in secondary lymphoid organs (SLOs).
During fetal development in mouse and man, ILC3s interact
with endothelial and mesenchymal tissue cells and are respon-
sible for the initiation of lymph node and Peyer’s patch organo-
genesis (Cupedo et al., 2009; van de Pavert and Mebius, 2010;
Onder et al., 2017). After birth, ILC3s reside in SLOs throughout
life, embedded within a specialized mesenchymal stromal niche
(Hoorweg et al., 2015). Elegant studies on mouse ILC3s have
clarified some functions of these SLO-resident ILC3s. Located
at the inter-follicular areas, ILC3s interact with memory
T cells, enhancing their survival (Kim et al., 2003; Withers
et al., 2011). Moreover, splenic ILC3s are involved in the activa-
tion of marginal zone B cells and influence the ensuing produc-
tion of antibodies (Magri et al., 2014). Finally, lymph node ILC3s
can process and present antigens in major histocompatibility
complex class II (MHC class II) and induce either T cell deletion
or T cell activation (Hepworth et al., 2015, 2013; von Burg et al.,
2014). Combined, a picture emerges in which mouse SLO-
residing ILC3s have distinct functional features that can poten-
tially affect multiple aspects of innate and adaptive immunity.
In contrast to these data on mouse ILC3s, knowledge on
SLO-residing human ILC3s is scarce.
Data on human SLO-residing ILC3 functionality is almost
exclusively derived from cells isolated from tonsils. Human
lymph node or splenic ILC3s have been described (Hoorweg
et al., 2012; Magri et al., 2014), but the full function and
phenotype of these cells remains to be established. The
ILC3s that reside in palatine tonsils resemble mucosal tissue
ILC3s in phenotype and function. They express the natural
cytotoxicity receptor (NCR) NKp44 and, in line with the associa-
tion of this receptor with active cytokine secretion, are avid
producers of ILC3 signature cytokines, including IL-22 andReports 21, 823–833, October 17, 2017 ª 2017 The Author(s). 823
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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granulocyte-macrophage colony stimulating factor (GM-CSF)
(Glatzer et al., 2013; Hoorweg et al., 2012).
Lymph nodes and spleen have long been recognized as
essential sites for activation and regulation of adaptive immune
cells. On average, the human body contains more than 500
lymph nodes (Trepel, 1974) yet only 5 tonsils. This implies that
at anymoment, the combined number of ILC3s residing in lymph
nodes will outnumber the sum of tonsil-resident ILC3s.
Insight in the immune phenotype of ILC3s residing in non-
reactive human SLOs is pertinent for a full understanding of
ILC3 biology and function. In this study, we set out to analyze
the immune phenotype and functionality of human ILC3s from
resting SLOs in the absence of inflammation or immune activa-
tion compared to those of ILC3s from inflamed tonsils and
peripheral blood (PB). By massive parallel sequencing of RNA
transcripts, we show that ILC3s in resting SLOs lack transcrip-
tion of the major ILC3 signature cytokine genes, irrespective of
NKp44 expression or activated phenotype. Nonetheless, this
substantial pool of resting ILC3s has the ability to produce
ILC3 signature cytokines in response to inflammatory stimuli.
Activation capability is controlled by the SLOmicroenvironment,
because PB ILC3s lack the appropriate cytokine receptors and
are cytokine unresponsive. Altogether, these data provide a
comprehensive multi-tissue transcriptomic dataset of human
ILC3s residing in SLOs and revise current views on human
ILC3s by identifying SLO-residing ILC3s as a substantial pool
of resting, non-cytokine-producing immune cells with the ability
to rapidly respond to activating signals from cells present in the
local microenvironment.
RESULTS
Signature Cytokines Are Absent from the Shared SLO
ILC3 Immune Transcriptome
To identify immunological functionalities of SLO-residing ILC3s,
we characterized the transcriptome of ILC3s (LinCD45+
CD127+cKit+CRTH2 NKp44 or NKp44+) by RNA sequencing
of purified populations of cells from non-reactive hepatic lymph
nodes and spleens, from recurrently inflamed pediatric tonsils,
and from healthy adult PB buffy coats. In lymph nodes and
blood, most ILC3s lacked expression of the NCR NKp44, while
spleens and tonsils contained both NKp44 and NKp44+ ILC3
populations (for gating strategy and distributions, see Figure S1).
ILC3 identity was confirmed by expression of RORgt protein,
with the highest expression in tonsil NKp44+ ILC3s (Figure 1A),Figure 1. SLO-Residing ILC3s Share a Transcriptional Signature
(A) Tonsil, lymph node, spleen, and blood samples were stained for RORgt exp
sentative of at least n = 3 are shown (full gating in Figure S1A).
(B) Transcription of key ILC3 transcription factors analyzed by RNA sequencing a
sorted ILC3 populations. As a negative control, bone marrow mesenchymal strom
n = 3; for spleen, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001 compared to PB or betw
bars represent mean ± SEM.
(C) Number of genes with significantly different expression (p < 0.05) between th
circle shows PB ILC3s versus SLO ILC3s.
(D) Principal component analysis (PCA) of ILC3s using genes within the gene on
resents an individual sample, with green dots marking NKp44 ILC3s and red do
(E) 50 highest transcribed genes common to all SLO ILC3s within the GO term ‘‘im
value of all depicted genes across the samples (n = 3–4, as in C). See also Tableand transcription of key transcription factors associated with
the ILC3 lineage, including ID2, RORC, NFIL3, and GATA3 (Fig-
ure 1B). Human bone marrow-derived stromal cells (Chen et al.,
2016) were used as a control population in these analyses. ILC3
lineage genes were either absent or expressed at background
levels in these cells, with the exception of NFIL3 (Figure 1B).
The latter is in line with public transcript data on stromal cell
populations in the mouse (http://www.immgen.org).
To identify transcripts associated with ILC3 tissue residency,
we analyzed differentially expressed genes between ILC3s iso-
lated from SLOs (lymph nodes, spleens, and tonsils) and from
PB. NKp44 ILC3s from resting lymph nodes and spleen were
transcriptionally comparable, with only 84 genes expressed at
significantly different levels (Figure 1C). In contrast, NKp44
ILC3s from inflamed tonsils differed in more than 400 genes
from the phenotypically similar ILC3s from either lymph nodes
or spleen (Figure 1C). The highest numbers of significantly
different genes were observed between NKp44+ cells from in-
flamed tonsils and NKp44 cells from either resting lymph nodes
(821 genes) or spleens (698 genes) (Figure 1C). In part, these dif-
ferences are likely explained by the inflamed environment of the
tonsils compared to the homeostatic environment of the lymph
nodes and spleens. The transcriptome of PB ILC3s was signifi-
cantly different compared to all SLO ILC3 subsets, with at least
1,800 genes expressed differentially (Figure 1C).
We decided to further focus on the transcripts related to
immunological functions of ILC3s from the different SLOs and
performed principle component analysis (PCA) based on genes
annotated within the gene ontology (GO) term ‘‘immune system
process’’ (for the list of genes used, see Table S1). ILC3s from
resting SLOs (lymph nodes and spleens), tonsils, and PB formed
distinct clusters (Figure 1D; Figure S2), suggesting that ILC3 im-
mune transcriptomes are shaped by local tissue microenviron-
ments (for genes contributing to PC1 and PC2, see Table S2).
To identify immunologically relevant genes expressed in ILC3s
and associated with SLO residency, we compiled an immune
gene signature common to all SLO-residing ILC3s, irrespective
of NKp44 expression or inflammatory status of the donor tissue.
To do so, the 50 genes with the highest expression across all
SLO-residing ILC3s and contained within the GO term ‘‘immune
system process’’ were selected (Table S3). These included
genes previously associated with ILC3 biology, e.g., LTB, ID2,
TNFRSF25 (encoding DR3), KLRB1 (encoding CD161), IL2RG
(CD132, common g chain of the IL-2 receptor), and TYROBP (en-
coding DAP12) (Figure 1E) (Ahn et al., 2015; Bjo¨rklund et al.,ression. CD19+ B cells were used as a negative staining control. Data repre-
nd plotted as FPKM (fragments per kilobase of exon per 106 reads mapped) in
al cells (MSCs) were taken along (n = 10). For PB, lymph node (LN), and tonsil,
een indicated groups; #p < 0.05 between MSC and any ILC3 populations. Error
e indicated ILC3 samples. The upper circle shows SLO ILC3s, while the lower
tology (GO) term ‘‘immune system process’’ (excluding NCR2). Each dot rep-
ts marking NKp44+ ILC3s. See also Figure S2 and Tables S1 and S2.
mune system process.’’ Z scores were calculated based on the average FPKM
s S1 and S3.
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Figure 2. Cytokine Transcription Is Independent of NKp44 Expression or Activation State
(A) Expression levels (FPKM) of selected cytokine genes previously associated with human ILC3s.
(B) Venn diagram showing the overlap of the number of genes that are significantly different (p < 0.05) between NKp44+ and NKp44 ILC3s in spleens (33 genes;
green circle) and tonsil (58 genes; red circle), as well as the genes differentially expressed in both organs (14 genes). See also Table S4.
(C) Expression levels (FPKM) of selected genes from B associated with T cell activation.
*p < 0.05, **p < 0.01,***p < 0.001 compared to PB or between indicated groups. (A and C) Error bars represent mean ± SEM.2016). We also identified genes not previously associated with
ILC3 function, such as TNFRSF18 (GITR) andCXCR4 (Figure 1E).
However, most striking was the absence of all ILC3 signature cy-
tokines, including IL22, CSF2 (encoding GM-CSF), and TNF,
which are considered to be constitutively expressed in inflamed
tonsillar ILC3s and intestinal ILC3s (Artis and Spits, 2015; Hazen-
berg and Spits, 2014). Altogether, these data show that ILC3s
from human SLOs share a functional immune signature that is
distinct from PB ILC3s and does not include cytokine genes
commonly associated with ILC3 function.
Cytokine Transcription Is Independent of NKp44
Expression
The SLO ILC3 immune transcriptome did not contain any ILC3
signature cytokines that are constitutively expressed by ILC3s
in inflamed tonsil and intestines. This could be explained by
only a low number of ILC3s within the tonsil transcribing these
cytokines, as is the case for non-inflamed tonsils (Bjo¨rklund
et al., 2016), or by differences in cytokine production between
the non-reactive SLOs and the inflamed tonsils. To elucidate826 Cell Reports 21, 823–833, October 17, 2017the cytokine profile of ILC3s residing in non-reactive SLOs, we
subsequently focused on transcription of cytokine genes in
ILC3s from the different SLOs. Signature genes such as IL22,
LTA, LTB, and TNF were transcribed by tonsil ILC3s yet either
absent or expressed at very low levels in lymph node and spleen
ILC3s (Figure 2A). Additional cytokines previously associated
with ILC3 function, such as LIF and IL2 (Cella et al., 2009; Crellin
et al., 2010b), followed a similar pattern of transcription (Fig-
ure 2A). The cytokine transcriptome of PB ILC3s was compara-
ble to that of ILC3s from lymph nodes and spleen, with the
exception of LTA and LTB, which were transcribed at higher
levels in PB ILC3s, similar to tonsil ILC3s (Figure 2A). These find-
ings indicate that ILC3s within human non-reactive SLOs are not
constitutively transcribing high levels of cytokine transcripts but
rather appear to be in a more resting immunological state.
Secretion of cytokines has been associated with expression of
NKp44 in ILC3s isolated from intestines or tonsil (Glatzer et al.,
2013; Hoorweg et al., 2012). Herewe show that in a non-inflamed
environment such as the spleen, IL-22 transcription is low in both
NKp44+ and NKp44 ILC3s (Figure 2A), indicating that active
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cytokine transcription is associated with inflammation, rather
than NKp44 expression. We next asked whether NKp44+ splenic
ILC3s show alternative signs of cellular activation in the absence
of cytokine transcription. We identified 14 immune genes that
were differentially expressed between NKp44+ and NKp44
ILC3s from both resting spleens and inflamed tonsils (Figure 2B;
Table S4). Many of these commonly different genes are involved
in cell migration, with NKp44+ ILC3s expressing lower levels of
SELL (encoding CD62L), CCR7, and S1PR1. This suggests
that NKp44+ and NKp44 ILC3s differ in their migration capacity,
possibly influencing their localization. High expression of SELL
was previously associated with a subset of more naive ILC3s
in resting tonsils (Bjo¨rklund et al., 2016), reinforcing the notion
thatSELLlo NKp44+ tonsil and spleen ILC3s in our analysis repre-
sent a more activated population. However, additional activa-
tion-associated transcripts involved in cytoskeletal function or
intracellular protein processing, previously linked to an activated
ILC3 subset in resting tonsils (Bjo¨rklund et al., 2016), were similar
between NKp44 and NKp44+ ILC3s from either spleens or in-
flamed tonsils (Figure S3). The only transcript associated with
cellular activation that we observed to be higher in NKp44+
ILC3s was the T cell activation marker CD2 (Figure 2C). Alto-
gether, these data show that NKp44 expression does not
associate with cytokine transcription or overt signs of cellular
activation and that splenic and tonsil NKp44+ ILC3s differ from
their NKp44 counterparts in genes involved in cell migration.
ILC3s in Human SLOs Transcribe Genes Involved in
Cellular Interactions
ILC3s from non-inflamed SLOs seem to function independently
of classical ILC3 cytokines, suggesting that these ILC3s could
have alternative functional roles. To address this possibility, we
analyzed expression of genes involved in functional properties
suggested for mouse lymphoid organ-residing ILC3s, including
cytokine production and support of adaptive immune cells (Cella
et al., 2009; Hepworth et al., 2015, 2013; Kim et al., 2003; Magri
et al., 2014; von Burg et al., 2014; Withers et al., 2011). We deter-
mined genes specifically expressed in both lymph node and
splenic NKp44 ILC3s compared to the phenotypically similar
NKp44 cells present in PB. This yielded 1,758 differentially ex-
pressed genes (Figure 3A). Subsequently, Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis identified
cytokine-cytokine receptor interactions and tumor necrosis fac-
tor (TNF) signaling pathways as significantly enriched in this gene
set (Figures 3B and 3C). In mouse and human SLOs, ILC3sFigure 3. SLO ILC3s Transcribe Genes Involved in Immune Interaction
(A) Venn diagram showing the number of genes that are significantly different (p <
PB ILC3s and NKp44 splenic ILC3s (2,649 genes; red circle) and the genes dif
pathway analysis.
(B and C) Heatmaps of genes obtained from KEGG pathway analysis of cytokin
significantly different (p < 0.05) in both LN and splenic ILC3s when compared to P
population.
(D) Expression levels (FPKM) of selected genes from (B).
(E) Heatmap of genes that were significantly different (p < 0.05) between both
calculated per gene based on average FPKM per ILC3 population.
(F) Expression levels (FPKM) of selected genes from (D).
(G) Expression levels (FPKM) of IL-23R in ILC3s from the analyzed tissues.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to PB or between indicated groups
828 Cell Reports 21, 823–833, October 17, 2017localize to the T-B interface (Hoorweg et al., 2015; Kim et al.,
2011). In line with this spatial positioning, lymph node and spleen
ILC3s expressed bothCXCR5 andCCR7 (Figure 3D). In addition,
ILC3s from resting SLOs expressed high levels of TNFSF11 and
of TNFRSF25 (encoding RANKL and death receptor [DR] 3,
respectively). Lymph node ILC3s in mouse can influence mem-
ory T cell survival through expression of TNF superfamily mem-
bers, independent of inflammatory cytokines (Kim et al., 2011;
Withers et al., 2012). Similar to those of mouse, human SLO
ILC3s expressed TNFSF8 and TNFSF4 (encoding the T cell co-
stimulating molecules CD30L and OX40L, respectively) (Fig-
ure 3D) (Kim et al., 2003, 2005; Withers et al., 2011, 2012).
ILC3s also transcribed the T cell-associated molecule TNFRSF4
(encoding OX40) (Figure 3D). All these TNF family members,
except for TNFSF8, were also transcribed by tonsil ILC3s (Fig-
ure 3D) and should thus be considered part of a more general
homeostatic SLO ILC3 transcriptional signature, expressed
independently of an inflammatory environment.
In the search for ILC3 immune genes associated specifically
with presence in non-inflamed SLOs, we focused on transcripts
expressed to significantly higher levels in NKp44 ILC3s from
lymph node and spleen in comparison to phenotypically similar
cells from tonsil and PB (Figures 3E and 3F). This revealed that
ILC3s in resting SLOs differentially transcribed several cytokine
receptor genes, including IL1R1, IL18R1, IL7R, IFNGR1, and
TGFBR2. In addition, the cytokine IL18 and the transcription
factor IKZF1, involved in inhibiting IL-2 production in T cells
(Bandyopadhyay et al., 2007; O’Brien et al., 2014; Thomas
et al., 2007), were transcribed to significantly higher levels in
NKp44 ILC3s from lymph node and spleen compared to
ILC3s from tonsil or blood (Figure 3F). The finding that IL1R1,
a major activating receptor for ILC3s, was more highly ex-
pressed in lymph node and spleen ILC3s compared to tonsil
ILC3s led us to analyze transcription of another important
ILC3-activating receptor: IL23R. In contrast to IL1R1, IL23R
transcription followed a pattern associated with the degree of
inflammation. Highest expression of IL23R transcription was
observed in tonsil ILC3s, lower levels were seen in lymph
node and spleen ILC3s, and transcription was very low in PB
ILC3s (Figure 3G).
Altogether, these transcriptomic profiles predict functional
roles for human SLO-residing ILC3s that include intercellular
communication with memory T cells via TNF family members
and receptiveness to environmental signals through expression
of cytokine receptors.s and Cytokine Responsiveness
0.05) between PB ILC3s and LN ILC3s (2,331 genes; green circle) and between
ferentially expressed in both datasets (1,758 genes) that were used for KEGG
e-cytokine receptor interaction (B) and TNF signaling pathway (C) that were
B ILC3s. Z scores were calculated per gene based on average FPKM per ILC3
LN and splenic ILC3s versus PB and NKp44 tonsillar ILC3s. Z scores were
. (D, F, and G) Error bars represent mean ± SEM.
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Figure 4. Non-reactive SLO ILC3s Can Be Activated
(A) Purified human ILC3s isolated from indicated tissues were cultured for 3 days with IL-23 and IL-1b (black bars) or left unstimulated (gray bars), and indicated
cytokines weremeasured in the culture supernatant using ELISA. Differences between unstimulated and stimulated conditions were calculated with theWilcoxon
signed-rank test; differences between ILC3 stimulated conditions were calculated by Mann-Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001 compared to PB or
between indicated groups. For IL-22, n = 5–13; for GM-CSF, n = 5–12; for TNF, n = 3–8; for IFN-g, n = 4–7; ND, not detected. See also Figure S4A.
(B) Purified ILC3s from PB, lymph nodes, and spleen were stimulated with IL-23 for 15 min (or left unstimulated), and phosphorylation of STAT3 (pStat3) was
measured by flow cytometry. Unfractionated blood mononuclear cells (MNCs) (PBMCs) stimulated with IL-6 were used as a positive assay control. Data shown
are representative of n = 3.
(C) qPCR analysis of IL23A and IL1B expression in mononuclear phagocytes (CD3CD19CD11b+HLA-DR+) (for full gating, see Figure S4B) sorted from tonsils
(n = 4) and spleens (n = 6). *p < 0.05, Mann-Whitney U test.
(A and C) Error bars represent mean ± SEM.SLO-Residing ILC3s Can Be Activated by Inflammatory
Signals
Our transcriptional definition of the immune status of ILC3s in
resting and inflamed human SLOs suggests that active cytokine
production is the result of local inflammation-related signals.
Furthermore, ILC3s in non-inflamed SLOs lack signature cyto-
kines yet transcribe genes associated with cellular interactions
and cytokine responses. Because SLOs are the primary sites of
immune cell activation, we hypothesized that ILC3swithin resting
SLOs should be able to initiate cytokine production in response
to signals associated with infection or inflammation. To test thishypothesis, we purified ILC3s from lymph nodes, spleen, tonsils,
and PB and stimulated these cells with IL-1b and IL-23. As ex-
pected, tonsil ILC3s responded to cytokine stimulation by secre-
tionof IL-22,GM-CSF, TNF-a, and interferong (IFN-g) (Figure 4A).
ILC3s from resting lymph nodes and spleens, which do not tran-
scribe cytokines directly ex vivo, had the ability to respond to
stimulation with IL-1b and IL-23 and secreted high levels of all
4 cytokines (Figure 4A). Stimulation with IL-23 alone was insuffi-
cient to evoke cytokine production in either splenic or tonsil
NKp44+ ILC3s, while IL-1b alone led to production of GM-CSF,
but not IL-22, in both cell types (Figure S4A). Altogether, theseCell Reports 21, 823–833, October 17, 2017 829
results show that even though ILC3s in resting SLOs are not
actively transcribing cytokines, they are receptive to inflamma-
tory signals and can convert to reactive cytokine-secreting cells.
In contrast to SLO ILC3s, the ILC3s isolated from PB showed
virtually no production of IL-22, GM-CSF, TNF-a, or IFN-g in
response to IL-23 and IL-1b (Figure 4A). This was in line with
the finding that transcripts for the receptors for IL-23 and IL-1
were virtually absent from this population (Figures 3F and 3G).
To determine whether transcriptional levels of IL23R trans-
lated into IL-23 responsiveness, STAT3 phosphorylation was
measured shortly after cytokine exposure of ILC3s. Upon stimu-
lation with IL-23, STAT3 was phosphorylated in ILC3s from
lymph nodes and spleens, similar to activation of total PBmono-
nuclear cells (PBMCs) with IL-6 (Figure 4B). In contrast, exposure
of PB ILC3s to IL-23 did not induce STAT3 phosphorylation (Fig-
ure 4B). Because all SLO-residing ILC3 populations can respond
to cytokine stimulation, steady-state differences in cytokine tran-
scription between inflamed and non-inflamed lymphoid tissues
are likely a reflection of the local cytokine milieu. To corroborate
this notion, we purified mononuclear phagocytes from non-in-
flamed spleens and inflamed tonsils and assessed transcription
of the ILC3-activating cytokines IL-23 and IL-1b (for gating, see
Figure S4B). Tonsil phagocytes transcribedmore IL23, and there
was a trend toward more IL1B (Figure 4C), indicating that the in-
flamed environment of the tonsil is likely enriched for ILC3-acti-
vating signals. These findings fit the proposed scenario in which
the circulating ILC3 pool is enriched for precursors to the ILC
lineage (Lim et al., 2017) and highlight the importance of signals
emanating from the SLO microenvironment to induce full ILC3
receptiveness to cytokine production, regulated at least partly
through acquisition of IL-23R expression and responsiveness
to local cytokines.
DISCUSSION
Here we present a cross-tissue transcriptomic comparison
of human ILC3s. We provide compelling evidence indicating
that most SLO-residing ILC3s are characterized by a resting
phenotype and, in contrast to mucosal tissue ILC3s, are not
constitutively transcribing the cytokines that are often consid-
ered synonymous with ILC3 function.
Although mainly described as mediators of inflammation and
guardians of homeostasis in epithelial and mucosal tissues, a
substantial population of ILC3s is present in SLOs in both
mice and humans (Bar-Ephraı¨m and Mebius, 2016). In humans,
functional studies on SLO-resident ILC3s mainly relied on cells
isolated from inflamed tonsils. Although these ILC3s are likely a
relevant population in the context of mucosal immunity and
barrier integrity, functional similarity to their more numerous
counterparts in non-inflamed SLOs might be limited. This is
not unlike adaptive immune cells that exist mostly as naive cells
in resting SLOs, while in tonsils, both germinal center B cells
and distinct populations of activated and memory T cells are
present (Nave et al., 2001; van Kempen et al., 2000). By using
resting, non-reactive hepatic lymph nodes and spleens, we
could identify functional traits of SLO-residing ILC3s in a direct
comparison with ILC3s from circulation or from inflamed pala-
tine tonsils.830 Cell Reports 21, 823–833, October 17, 2017ILC3s from non-inflamed SLOs, inflamed tonsils, and PB all
formed distinct clusters in PCA, and this was irrespective of
NKp44 expression status. The differential clustering of lymph
node and spleen ILC3s versus tonsil ILC3s was also reflected
in transcriptional changes of immune-related genes. ILC3s
from inflamed tonsils are the most immunologically active ILC3
population in our analyses, with the highest levels of transcription
of cytokines and activation markers. In contrast, ILC3s in non-in-
flamed SLOs lack transcription ofmost activationmarkers and of
signature cytokines such as IL-22 and GM-CSF. A similar
absence of cytokines and activation markers was obvious in
PB ILC3s, even though the highly divergent clustering of these
innate lymphoid cells (ILCs) is likely influenced by this population
containing ILC precursors with the ability to differentiate into all
ILC subsets (Lim et al., 2017). This was confirmed by the low
levels of RORC transcription in the PB ILC subset (Figure 1B).
Curiously, this did not translate into lower levels of RORgt protein
(Figure 1A). Whether this is due to technical issues or reflects a
true biological phenomenon remains to be asserted. We did
not detect transcripts associated with T or B cell lineage devel-
opment (RAG1, RAG2, EBF, or LMO2) in PB ILC, suggesting
that these cells are committed to the ILC lineage (data not
shown) (Lim et al., 2017).
Through the analyses of ILC3s in non-reactive spleens, we had
the opportunity to investigate the functional association of
NKp44 expression with ILC3 cytokine transcription. In line with
previous findings (Glatzer et al., 2013; Hoorweg et al., 2012),
our dataset links NKp44 expression to cytokine secretion in
ILC3s from inflamed tonsils. However, in contrast to tonsil-
residing ILC3s, NKp44 expression on ILC3s from non-reactive
spleens is uncoupled from cytokine production, because IL-22,
GM-CSF, and other signature cytokines are absent from both
NKp44+ and NKp44 splenic ILC3s. Moreover, in both spleen
and inflamed tonsil, NKp44 expression did not enrich for activa-
tion-associated genes, as previously defined on resting tonsil
NKp44+ ILC3s (Bjo¨rklund et al., 2016). This notwithstanding,
NKp44+ ILC3s were reported to appear in lymph nodes of pa-
tients with rheumatoid arthritis (Rodrı´guez-Carrio et al., 2017).
The ability to respond to activating cytokines, in particular
IL-23 and IL-1b, is a feature that is shared by all SLO-residing
ILC3s, regardless of whether they are in an inflamed or a non-in-
flamed environment. Only ILC3s from inflamed tonsils actively
secrete the cytokines downstream of IL-23 and IL-1b activation,
which revealed that the lymph nodes and spleen collectively
contain a substantial reservoir of ILC3s with the capacity to be
activated by local cytokine signals. This was corroborated by
our in vitro activation studies, which showed that ILC3s from
lymph nodes and spleen can respond to cytokine stimulation
and secrete high amounts of IL-22, GM-CSF, TNF-a, and
IFN-g. Furthermore, mononuclear phagocytes from tonsils pro-
duced more IL-23 compared to phagocytes from spleen, again
emphasizing that differences in the ILC3 microenvironment
determines their overall activation profile.
The ability to respond to cytokines was absent from PB ILC3s.
It is likely that this is largely because of their precursor status (Lim
et al., 2017), yet STAT3 phosphorylation and IL-23R responsive-
ness are absent, which also suggests that any mature ILC3s in
blood might need to initiate cytokine receptor transcription to
become responsive to inflammatory cytokines. It is tempting to
speculate that this will be regulated by local signals in the SLO
microenvironment, but this will need to be experimentally
addressed.
Besides avid cytokine producers, mouse ILC3s have been
implicated in other immune-related functions within SLOs. In
human non-inflamed SLOs, ILC3s express transcripts for
many TNF family members known to affect T cell function (i.e.,
TNFSF4 and TNFSF8, encoding OX40L and CD30L, respec-
tively). Although expression of OX40L by ILC3s and its functional
consequences have been described in mice (Kim et al., 2003,
2005; Withers et al., 2011), human SLO ILC3s also transcribed
TNFRSF4 (OX40). The functionality and consequences of OX40
expression on ILC3s remains unexplored, but it could allow
for co-activation of ILC3s by antigen-presenting cells or by
neighboring ILC3s and warrants future investigation. Human
SLO-residing ILC3s also transcribed IKZF1, which restricts IL-2
production in activated CD8+ and anergic CD4+ T cells (Bandyo-
padhyay et al., 2007; O’Brien et al., 2014; Thomas et al., 2007).
This observation might represent a previously unrecognized
regulator of ILC3 proliferation and activation.
Altogether, our findings redefine current views on human
in situ ILC3 immunology and provide a detailed dataset of
human SLO-residing ILC3s. These cells are in a resting state
yet form a significant pool of cells capable of responding to in-
flammatory signals. Whether they remain in the lymphoid envi-
ronment upon activation or migrate to affected tissues, similar
to adaptive lymphocytes, has yet to be investigated, although
data from mouse studies provide evidence for the latter (Kim
et al., 2015; Yang et al., 2016). Altogether, the findings presented
in the current study allow for investigation of the functional
consequences of ILC3 activation and for exploring of whether
alterations in ILC3 phenotype can be exploited as sensitive indi-
cators of local immune activation in response to infection or
malignancy.EXPERIMENTAL PROCEDURES
Human Tissues
PBMCswere isolated frombuffy coats of anonymous adult blood donors (San-
quin Blood Supply, the Netherlands) by gradient centrifugation on Lympho-
prep (d = 1.077, Fresenius Kabi Norge, Berg i Østfold, Norway). PBMCs
were subsequently washed twice in cold PBS (B. Braun Melsungen, Melsun-
gen, Germany) supplemented with 10% v/v donor plasma.
Palatine tonsils were obtained during routine pediatric tonsillectomies
at the Department of Otolaryngology, Slotervaart Hospital, Amsterdam, the
Netherlands, and Sophia Children’s Hospital, Rotterdam, the Netherlands.
Hepatic lymph node and spleen tissues were collected post-mortem during
multi-organ transplantation procedures at the Erasmus University Medical
Center, Rotterdam, the Netherlands. Tissue was cut into small pieces, and
cell suspensions were prepared by disrupting the tissue with a GentleMacs
dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) in the presence
of 0.5 mg/mL Collagenase D (Sigma Aldrich, St. Louis, MO, USA). Mononu-
clear cells were further isolated by gradient centrifugation on Lymphoprep
(d = 1.077, Fresenius Kabi Norge).
All human tissues were collected after approval by the Medical Ethical Com-
mittee of the VU University Medical Center (Amsterdam, the Netherlands) or
the Erasmus UniversityMedical Center (Rotterdam, the Netherlands), in accor-
dance with the Declaration of Helsinki and according to Dutch law. Tissues are
used anonymously, and no information is available on age or gender of the
donors.Flow Cytometry
For cell sorting of ILC3s,mononuclear cell fractions of all tissueswere enriched
for ILC3s using the CD117 MicroBead kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer’s protocol, followed by positive se-
lection using LS columns (Miltenyi Biotec). Cell suspensions were subse-
quently labeled with the following antibodies: CD45-phycoerythrin (PE)-Cy7
(clone HI30), CD127-APCe Fluor 780 (eBioRDR5), and CD94-FITC (DX22)
(all eBioscience, San Diego, CA, USA); NKp44-Alexa Fluor 647 (P44-8,
BioLegend, San Diego, CA, USA); a lineage cocktail containing CD3
(MEM57), CD19 (LT19), CD14 (MEM15), and CD34 (4H11) (all PE-Texas red,
all Exbio, Vestec, Czech Republic); and CRTH2-PerCP-Cy5.5 (BM16, BD
Biosciences, Mountain View, CA, USA). From the CD117-negative fraction,
mononuclear phagocytes were sorted after labeling with CD11c-PE (Bu15,
BioLegend), HLA-DR/DP/DQ-FITC (Tu39, BD Biosciences), CD14-Alexa Fluor
700 (HCD14, BioLegend), and CD19-PE-Texas red (LT19, Exbio). For both
ILC3 and dendritic cell (DC) sorting, dead cells were excluded using DAPI.
Sorting was performed using a FACSAria III sorter (BD Biosciences, Mountain
View, CA, USA).
For flow cytometric determination of RORgt, anti-RORgt-PE (AFKJS-9)
was added to the antibody cocktail. Fixation and permeabilization were per-
formed using the Foxp3/Transcription Factor Fixation/Permeabilization Kit
(eBioscience, San Diego, CA, USA).
Cell Culture and Stimulation
Fluorescence-activated cell sorting (FACS)-purified ILC3s (25,000 cells) were
cultured in 200 mL DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 10% (v/v) fetal calf serum (HyClone, GE Healthcare
Life Sciences, Loga, UT, USA), penicillin, streptomycin, and L-glutamine in
the presence of IL-7 (PeproTech, Rocky Hill, NJ, USA) and stem cell factor
(SCF; R&D Systems, Minneapolis, MN, USA) (both at 10 ng/mL) for 3–5 days
before stimulation.
Cells were stimulated with IL-23 (50 ng/mL) and IL-1b (10 ng/mL) in the pres-
ence of IL-7 and SCF (10 ng/mL), unless indicated otherwise, for 3 days before
measurement of cytokine release by ELISA. Quantification of IL-22, TNF-a,
and GM-CSFwas performed using the DuoSet ELISA Kits (R&D Systems, Min-
neapolis, MN, USA) according the manufacturer’s protocol.
For detection of phosphorylated STAT3 (pSTAT3), FACS-purified ILC3s
were stimulated for 15min with IL-23 (100 ng/mL) (R&D Systems, Minneapolis,
MN, USA) or left untreated. Next, cells were fixed and permeabilized (BD Cy-
tofix/Cytoperm, BD Biosciences, Mountain View, CA, USA) for 15 min at 37C,
followed by additional fixation with 90% (v/v) methanol (20C) on ice for
30 min. Cells were then washed with permeabilization and wash solution
(BD Cytofix/Cytoperm), and pSTAT3 was stained for 1 hr at room temperature
(RT) using mouse-anti-STAT3-Alexa Fluor 647 (pY705, clone 4/P-STAT3, BD
Phosflow) IgG2a antibody, or, isotype control antibodies.
Analysis was performed on a LSR II (BD Biosciences, Mountain View, CA,
USA). Further analysis was done using FlowJo v.10 for Microsoft (Tree Star,
San Carlos, CA). Gates were set based on isotype controls and/or unstimu-
lated cells.
Sample Preparation and RNA Sequencing
For RNA sequencing, ILC3s were sorted from PB (n = 3), hepatic lymph nodes
(n = 3), spleens (n = 4), and tonsils (n = 3). Cells were FACS sorted directly into
lysis buffer containing tris(2-carboxyethyl)phosphine (TCEP; Macherey-Nagel,
D€uren, Germany) and stored at 80C until further processing. RNA was iso-
lated according the manufacturer’s protocol (NucleoSpin XS Kit, Macherey-
Nagel), omitting the addition of carrier RNA. RNA quality was measured on a
RNA 6000 Pico Kit (Agilent Technologies, Amstelveen, the Netherlands) using
a 2100 Bioanalyzer (Agilent Technologies). 100 pg of high-quality RNA (RNA
integrity number [RIN] = 8.37 ± 0.55 [average ± SD]) was converted into
cDNA using the SMART-Seq (v.3) Ultra Low Input RNA Kit (Clontech Labora-
tories, Mountain View, CA, USA) with 15 cycles of amplification. Amplified and
Covaris-fragmented cDNA was quality-checked on a High Sensitivity DNA
chip (Agilent Technologies) and further processed according the TruSeq
Nano DNA Library Preparation Kit (Illumina, San Diego, CA, USA). Samples
were sequenced on the HiSeq 2500 platform (Illumina, San Diego, CA, USA).
Data were processed as described previously (Chen et al., 2016). In brief,Cell Reports 21, 823–833, October 17, 2017 831
SMARTer adapters were trimmed with Cutadapt, and the resulting sequences
were aligned to the human RefSeq transcriptome and reference genome (build
HG19) using TopHat2 (Kim et al., 2013). Normalization and quantification were
performed using Cufflinks, resulting in a per gene abundance estimation
measured in fragments per kilobase of exon per 106 reads mapped (FPKM)
(Trapnell et al., 2012). Fragment counts were determined per gene with
HTSeq-count and subsequently used for differential expression analysis using
the DESeq2 package (Anders and Huber, 2010). Multiple testing correction
was performed with the Benjamini-Hochberg procedure to control the false
discovery rate (FDR) as part of the DESeq2 procedure. PCA was performed
on the fragment counts using the R environment.
RNA sequencing data from human bone marrow stromal cells (n = 10) were
generated in a similar manner and published previously (Chen et al., 2016).
RNA Isolation, cDNA Synthesis, and qPCR
Mononuclear phagocytes were FACS sorted directly into lysis buffer contain-
ing TCEP (Macherey-Nagel, D€uren, Germany) and stored at80C until further
processing. RNA was isolated according the manufacturer’s protocol (Nucle-
oSpin XS Kit, Macherey-Nagel). RNA was converted into cDNA using the
SensiFAST cDNA Synthesis Kit (Bioline, London, UK) according to the
manufacturer’s instructions. For qPCR, the SensiFAST SYBR Lo-ROX Kit
(Bioline) was used according the manufacturer’s instructions with the addition
of MgCl2 to a final concentration of 4 mM on a 7500 Fast Real-Time PCR
System (Applied Biosystems). All reactions were performed in duplicate and
were normalized to the expression of GAPDH. Relative expression was calcu-
lated by the cycling threshold (CT) method as 2dCt. Primer sequences are as
follows: GAPDH (forward, 50-GTCGGAGTCAACGGATT-30; reverse, 50-AAG
CTTCCCGTTCTCAG-30), IL23A (forward, 50-TGGGACACATGGATCTAAG-30;
reverse, 50-GCTCCCCTGTGAAAATATC-30), IL1B (forward, 50-CCTGCCCA
CAGACCT-30; reverse, 50-GGACCAGACATCACCAAG-30).
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